A recently identified RSK–LARG–ROCK pathway suggests that in glioma cells, RSK may also inhibit MYPT1 and promote motility through phosphorylation and activation of the LARG RhoGEF, which increases RhoA activation (84). Here, RPS6KA2 is linked to central nervous system cancer.